Sylvie Zanetta

3.9k total citations
63 papers, 1.5k citations indexed

About

Sylvie Zanetta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Sylvie Zanetta has authored 63 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 14 papers in Otorhinolaryngology. Recurrent topics in Sylvie Zanetta's work include Head and Neck Cancer Studies (14 papers), Cancer Treatment and Pharmacology (11 papers) and Lung Cancer Treatments and Mutations (10 papers). Sylvie Zanetta is often cited by papers focused on Head and Neck Cancer Studies (14 papers), Cancer Treatment and Pharmacology (11 papers) and Lung Cancer Treatments and Mutations (10 papers). Sylvie Zanetta collaborates with scholars based in France, United States and Belgium. Sylvie Zanetta's co-authors include Jean‐Pierre Droz, J. Guigay, François Ghiringhelli, Nicolás Isambert, Anne-Françoise Dillies, Gwénaëlle Gravis, Stéphane Culine, Stéphane Oudard, Stéphanie Henry and Éric Raymond and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Sylvie Zanetta

62 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvie Zanetta France	20	808	598	529	251	248	63	1.5k
Desirée Hao Canada	23	842 1.0×	633 1.1×	469 0.9×	201 0.8×	282 1.1×	90	1.5k
Eng-Huat Tan Singapore	17	772 1.0×	623 1.0×	329 0.6×	223 0.9×	143 0.6×	34	1.3k
Morena Fasano Italy	20	680 0.8×	535 0.9×	605 1.1×	244 1.0×	139 0.6×	63	1.4k
Jin‐Hyoung Kang South Korea	25	1.3k 1.6×	1.3k 2.2×	624 1.2×	418 1.7×	284 1.1×	98	2.2k
Zhihuang Hu China	19	1.0k 1.2×	601 1.0×	514 1.0×	387 1.5×	205 0.8×	53	1.6k
E. Neely Atkinson United States	16	500 0.6×	469 0.8×	450 0.9×	132 0.5×	315 1.3×	28	1.6k
K. Syrigos Greece	23	1.1k 1.4×	638 1.1×	388 0.7×	288 1.1×	246 1.0×	73	1.9k
Jessica Menis Italy	21	1.2k 1.4×	1.1k 1.9×	381 0.7×	363 1.4×	145 0.6×	76	1.9k
Veronica Lonati Italy	22	1.3k 1.6×	656 1.1×	296 0.6×	405 1.6×	384 1.5×	42	1.8k
Tak Yun South Korea	24	1.4k 1.7×	1.3k 2.1×	598 1.1×	480 1.9×	403 1.6×	81	2.3k

Countries citing papers authored by Sylvie Zanetta

Since Specialization

Citations

This map shows the geographic impact of Sylvie Zanetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Zanetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Zanetta more than expected).

Fields of papers citing papers by Sylvie Zanetta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Zanetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Zanetta. The network helps show where Sylvie Zanetta may publish in the future.

Co-authorship network of co-authors of Sylvie Zanetta

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Zanetta. A scholar is included among the top collaborators of Sylvie Zanetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Zanetta. Sylvie Zanetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertaut, Aurélie, Alice Hervieu, Sylvie Zanetta, et al.. (2025). FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial. Future Oncology. 21(6). 699–706. 3 indexed citations

Jacob, Pierre, Isabelle Desmoulins, Sylvie Zanetta, et al.. (2024). Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience. Cancers. 16(2). 280–280. 1 indexed citations

Borel, Christian, Xu-Shan Sun, Alexandre Coutté, et al.. (2024). Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiotherapy and Oncology. 197. 110329–110329. 2 indexed citations

Fayette, Jérôme, Caroline Even, Laurence Digue, et al.. (2023). NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). SHILAP Revista de lepidopterología. 2(1). e000065–e000065. 6 indexed citations

Michel, Loren S., Antonio Jimeno, Ammar Sukari, et al.. (2023). 859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. Annals of Oncology. 34. S558–S558. 8 indexed citations

Dufresne, Armelle, Olivier Huillard, Cécile Dalban, et al.. (2022). 465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program. Annals of Oncology. 33. S753–S753. 2 indexed citations

Borel, Christian, Xiangdong Sun, Alexandre Coutté, et al.. (2020). 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial. Annals of Oncology. 31. S660–S660. 4 indexed citations

Even, Caroline, Amaury Daste, Jérôme Fayette, et al.. (2020). 917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis. Annals of Oncology. 31. S662–S662. 1 indexed citations

Fumet, Jean David, Nicolás Isambert, Alice Hervieu, et al.. (2018). Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open. 3(4). e000375–e000375. 41 indexed citations

10.

Guigay, J., François Bidault, Jérôme Fayette, et al.. (2016). Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR. Annals of Oncology. 27. vi340–vi340. 1 indexed citations

11.

Ravaud, Alain, Stéphane Oudard, Marc de Fromont, et al.. (2015). First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Annals of Oncology. 26(6). 1123–1128. 121 indexed citations

12.

Guigay, J., Jérôme Fayette, Anne-Françoise Dillies, et al.. (2015). Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Annals of Oncology. 26(9). 1941–1947. 100 indexed citations

13.

Mirjolet, Céline, et al.. (2013). Ré-irradiations des cancers de la tête et du cou : état du concept et voies de développement. Cancer/Radiothérapie. 17(5-6). 508–512. 4 indexed citations

14.

Isambert, Nicolás, Gilles Freyer, Sylvie Zanetta, et al.. (2012). Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(6). 1743–1750. 31 indexed citations

15.

Freyer, Gilles, Nicolás Isambert, Benoît You, et al.. (2012). Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 107(4). 598–603. 17 indexed citations

16.

Favier, Laure, Nicolás Isambert, Sylvie Zanetta, et al.. (2007). Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. The Breast. 17(1). 36–41. 6 indexed citations

17.

Moluçon‐Chabrot, Cécile, Nicolás Isambert, L. Benoît, et al.. (2006). Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anti-Cancer Drugs. 17(10). 1211–1217. 12 indexed citations

18.

Extermann, Martine, G. Albrand, Hongbin Chen, et al.. (2003). Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?. Journal of Clinical Oncology. 21(17). 3214–3219. 108 indexed citations

19.

Terret, C., Sylvie Zanetta, Henri Roché, et al.. (2003). Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). European Journal of Cancer. 39(8). 1097–1104. 41 indexed citations

20.

Tranchand, Brigitte, Sylvie Zanetta, Aline Guillot, et al.. (1999). A Sensitive Docetaxel Assay in Plasma by Solid-Phase Extraction and High Performance Liquid Chromatography – UV Detection: Validation and Suitability in Phase I Clinical Trial Pharmacokinetics. Investigational New Drugs. 17(4). 325–333. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact